NewAmsterdam Pha SEC Filings

Louise Frederika Kooij, Chief Accounting Officer and director of NewAmsterdam Pharma Co. N.V. (NAMS), reported multiple transactions on 09/09/2025. The filing shows an acquisition of 150,000 ordinary shares at $10.00 and contemporaneous dispositions of 53,104 shares at a weighted average $25.31 and 96,896 shares at a weighted average $26.11, reflecting sales executed across prices in the ranges disclosed. The filing also reports derivative activity: an option with a $10 exercise price (granted 11/22/2022) covering 150,000 underlying shares that vest monthly over four years beginning 12/01/2022. After the reported transactions the schedules list beneficial ownership figures shown in the form, and the report is signed on 09/10/2025.

James N. Topper, a director, reported purchases of NewAmsterdam Pharma Co N.V. ordinary shares on 09/08/2025. The Form 4 shows 1,260 shares acquired at a weighted average price of $24.99 (prices ranged from $24.86 to $25.00). Following the transaction, the filing reports 3,027,864 shares held indirectly by Frazier Life Sciences X, L.P. and 3,801,000 shares held indirectly by Frazier Lifesciences Sponsor LLC. The securities are held indirectly through a partnership and sponsor entities for which the reporting person is a managing member; the filing disclaims direct beneficial ownership except for pecuniary interest. The form is signed by an attorney-in-fact on behalf of Mr. Topper dated 09/10/2025.

NewAmsterdam Pharma Company N.V. insider activity is reported under Rule 144 for ordinary shares. The filer indicates an intended sale of 150,000 ordinary shares through J.P. Morgan Securities LLC with an aggregate market value of $3,780,000, and lists the approximate sale date as 09/09/2025 on NASDAQ. The shares were acquired on 11/22/2022 via an equity compensation exercise-and-sell transaction from the issuer, and payment is listed as cash. The filing also discloses two prior share sales by the same person in the past three months totaling 26,342 shares for gross proceeds of $658,999.39.

Louise Kooij, Chief Accounting Officer, filed a Form 4 reporting insider sales of NewAmsterdam Pharma Co N.V. The filing shows a sale on 09/03/2025 of 18,073 ordinary shares at a weighted average price of $25.09 per share. After the transaction the reporting person beneficially owns 15,000 shares directly. The filing includes a broker-provided weighted average price and notes that the full price range was not available at filing.

The form is a routine Section 16 disclosure signed on 09/05/2025 and does not include other transactions or derivative positions. All details reported are limited to the specific non-derivative sale and the post-transaction ownership reported by the insider.

Louise Frederika Kooij, the reporting person and Chief Accounting Officer of NewAmsterdam Pharma Company N.V. (ticker: NAMSW), executed a transaction dated 09/02/2025 reported on Form 4. The filing shows the acquisition of 18,073 ordinary shares through the exercise of an option and reports total beneficial ownership of 33,073 ordinary shares following the transaction. The option exercised had an exercise price of EUR 1.16392, was originally granted to replace an earlier award, and included a vesting schedule described in the filing. The filing also discloses that the securities were previously held indirectly through LouFre Management B.V. for the reporting person’s benefit. The Form 4 is signed by the reporting person on 09/04/2025.

NewAmsterdam Pharma Company N.V. (NAMSW) reported a Form 144 notice showing a proposed sale of 18,073 ordinary shares (nominal value EUR 0.12) with an aggregate market value of $434,655.65 to be executed through Cooperatieve Rabobank U.A. on the Nasdaq Global Market on 09/03/2025. The shares were acquired on 09/02/2025 via an option exercise from NewAmsterdam Pharma Company N.V., paid in cash. The filer also reported a prior sale of 8,269 shares on 08/25/2025 generating $205,547.82. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insider sale by NewAmsterdam Pharma Company N.V. officer and director. The reporting person, Louise Frederika Kooij, identified as the company's Chief Accounting Officer and a director, reported a sale of 8,269 ordinary shares on 08/25/2025 at a weighted average price of $24.86 per share. After the reported sale, the filing shows the reporting person beneficially owned 15,000 ordinary shares (direct ownership). The form notes the reported price is a weighted average from multiple transactions priced between $24.74 and $24.92, and that the filer can provide the exact share counts per trade on request.

NewAmsterdam Pharma Company N.V. (NAMSW) insider Louise Kooij filed a Form 144 reporting a proposed sale of 8,269 ordinary shares (nominal value EUR 0.12). The shares were acquired by RSU vesting on 03/26/2025 and the broker listed is Cooperatieve Rabobank U.A., Utrecht. The filing shows an approximate aggregate market value of $208,296.11 and indicates an intended sale on 08/25/2025 on the Nasdaq Global Market. The issuer's total shares outstanding are reported as 112,628,458. The filer attests there is no undisclosed material adverse information and includes the standard signature/representation language required by the form.